pre-IPO PHARMA

COMPANY OVERVIEW

Catamaran Bio is developing novel, off-the-shelf CAR-NK cell therapies designed to treat a broad range of cancers, including solid tumors. Our proprietary capabilities enable us to harness the natural cancer-fighting properties of NK cells and enhance and tailor their effectiveness with the power of synthetic biology and innovative non-viral cell engineering. We are using our TAILWINDTM Platform, an integrated suite of technologies, to specifically address the end-to-end methods of engineering, processing and manufacturing NK cells and rapidly advance our pipeline of CAR-NK cell therapy programs. Our team combines experienced biopharmaceutical leadership with founding scientists who are pioneers in NK cell biology, engineering, manufacturing and clinical application. Catamaran is backed by leading financial and corporate investors, including SV Health Investors, Sofinnova Partners, Lightstone Ventures, Takeda Ventures and Astellas Venture Management.


LOCATION

  • Cambridge, MA, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://catamaranbio.com/


    CAREER WEBSITE

    https://catamaranbio.com/careers/


    SOCIAL MEDIA


    INVESTORS

    astellas-venture-management lightstone-ventures sofinnova-partners sv-health-investors takeda-ventures university-minnesota


    PRESS RELEASES


    Mar 14, 2023

    Catamaran Bio selects OmniaBio as partner to develop and manufacture allogeneic CAR-NK cell therapies


    Nov 10, 2022

    Catamaran Bio Presents Preclinical Efficacy Data for Two Allogeneic CAR-NK Cell Therapies for Solid Tumors at SITC 2022 Annual Meeting


    Oct 5, 2022

    Catamaran Bio to Present Preclinical Efficacy Data for Allogeneic CAR‑NK Cell Therapies to Treat Solid Tumors at SITC Annual Meeting


    May 16, 2022

    Catamaran Bio Presents Preclinical Data Supporting Novel Engineered CAR-NK Cell Therapies For Treating Solid Tumors


    May 2, 2022

    Catamaran Bio to Present Preclinical Data at ASGCT Annual Meeting to Support CAR-NK Approach for Solid Tumors


    For More Press Releases


    Google Analytics Alternative